Healthcare / Drug Manufacturers - Specialty & GenericKSE
$88300.00
-700.00 (-0.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $7.4B · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$585.8B
P/E
6.4x
↓EV/EBITDA
6.3x
↓ROE
8.0%
↑Gross Margin
31.9%
↓Debt/Equity
0.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.1%
FCF CAGR
—
FCF margin
11.8%
FCF / Net income
1.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.43T · net income $90.94B · FCF $168.77B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1429.77B | $1429.77B | $1333.23B | $1132.00B | $1014.86B |
| Net Income | $90.94B | $90.94B | $58.02B | $57.99B | $11.15B |
| EBITDA | $178.09B | $178.09B | $194.87B | $162.65B | $103.20B |
| EPS | 13718.45 | 13718.45 | 8494.67 | 8744.46 | 1681.59 |
| Gross Margin | 31.9% | 31.9% | 30.6% | 33.1% | 29.0% |
| Operating Margin | 6.8% | 6.8% | 6.2% | 6.8% | 3.7% |
| Net Margin | 6.4% | 6.4% | 4.4% | 5.1% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.58 | 0.58 | 0.70 | 0.68 | 0.56 |
| Current Ratio | 0.79 | 0.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $168.77B | $168.77B | $7.43B | $-825.3M | $-2.73B |
| Returns | |||||
| ROE | 8.0% | 8.0% | 5.5% | 5.7% | 1.1% |
| Valuation | |||||
| P/E | 6.44 | 6.44 | 11.62 | 10.99 | 55.49 |
| EV/EBITDA | 6.32 | 6.32 | 6.65 | 7.44 | 10.43 |
| P/B | 0.51 | 0.51 | 0.64 | 0.63 | 0.63 |
| Growth & Yield | |||||
| Revenue Growth | 7.2% | 7.2% | 17.8% | 11.5% | — |
| EPS Growth | 61.5% | 61.5% | -2.9% | 420.0% | — |
| Dividend Yield | 1.9% | 1.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-17.0%
EPS terminal req.
$7835.15
Spread vs growth
78.5%
5Y implied EPS CAGR
-7.1%
EPS terminal req.
$9480.54
Spread vs growth
68.6%
10Y implied EPS CAGR
1.1%
EPS terminal req.
$15268.50
Spread vs growth
60.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.3%
Start / end P/E
11.5x → 6.5x
EPS bridge
8494.67 → 13718.45
Residual
-26.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.